Motion-controlled mobile games to improve thinking in people with schizophrenia

The Effect of a 2-month Somatic Serious Games on the Cognition of Schizophrenia Patients

Not applicable Interventional Shanghai Mental Health Center · NCT07557381

This project will try a motion-based smartphone game to improve thinking skills in adults with stable schizophrenia.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment84 (estimated)
Ages18 Years to 45 Years
SexAll
SponsorShanghai Mental Health Center Academic / other
Locations1 site (Shanghai)
Trial IDNCT07557381 on ClinicalTrials.gov

What this trial studies

Researchers developed a somatosensory interactive game that uses the gyroscope of mobile devices to train multiple cognitive domains relevant to schizophrenia. Adults with ICD-10 schizophrenia who are clinically stable and able to use a smartphone will be randomized to the game-based intervention versus usual care or control conditions. Standardized cognitive tests will be administered before and after the intervention to measure changes in attention, memory, and other cognitive functions. The trial is designed to evaluate both effectiveness and feasibility in a hospitalized Shanghai patient population.

Who should consider this trial

Good fit: Ideal candidates are adults 18–45 with ICD-10 schizophrenia who are clinically stable, can use a smartphone or tablet, have basic education, and are registered and hospitalized in the participating Shanghai mental health wards.

Not a fit: Patients with acute psychosis, severe motor or sensory impairments, inability to use mobile devices, those outside the age range, or not registered/hospitalized at the participating Shanghai centers are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, the game could improve memory, attention, and everyday thinking while making cognitive rehabilitation more engaging and easier to access.

How similar studies have performed: Previous small studies of serious games and sensory-interactive interventions have shown promising cognitive and engagement benefits, but large randomized trials in schizophrenia are still limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Registered in the Shanghai Mental Health Information Management System and hospitalized in the designated district-level mental health center wards;
2. Schizophrenia patients meeting the diagnostic criteria of schizophrenia in the International Classification of Diseases (ICD-10);
3. 18 - 45 years old;
4. Good self-care ability;
5. Clinically stable (without acute exacerbation) for at least 1 week before enrollment, with a stable dose of antipsychotic drugs or other concomitant psychotropic drugs for at least 1 week;
6. No hand disabilities, and can use mobile phones or tablets normally;
7. Have a primary school education or above;
8. Normal vision and hearing, or within the normal range after correction;
9. Own and be able to independently use a smart phone or other electronic devices;
10. Patients and their families have given informed consent to this study, and voluntarily cooperate to participate in the intervention and sign the informed consent form.

Exclusion Criteria:

1. not reside in Shanghai after discharge;
2. suffering from serious physical or brain organic diseases;
3. comorbid with other psychotic disorders.

Where this trial is running

Shanghai

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions SchizophreniaCognitionGame-Based Intervention
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.